[
  {
    "ts": null,
    "headline": "Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.",
    "summary": "Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.",
    "url": "https://finnhub.io/api/news?id=0622b5dd71ba4d46b5d12049e3d283a02a5e7da194b12486ae101a4795827d78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736427603,
      "headline": "Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.",
      "id": 132349387,
      "image": "https://media.zenfs.com/en/ibd.com/e1eeaef96933bc3e739bae513ec3f5e4",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.",
      "url": "https://finnhub.io/api/news?id=0622b5dd71ba4d46b5d12049e3d283a02a5e7da194b12486ae101a4795827d78"
    }
  },
  {
    "ts": null,
    "headline": "Buy The Dip: SCHD's Top Holdings Show That It Is Way Too Cheap",
    "summary": "Discover why SCHD is a clear buy with a look at its top 10 holdings and why they make it an attractive investment opportunity right now.",
    "url": "https://finnhub.io/api/news?id=3b68bfa866454efa7af7ce3949bd40eddda968966891067ff52185ad91becf1d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736424000,
      "headline": "Buy The Dip: SCHD's Top Holdings Show That It Is Way Too Cheap",
      "id": 132349330,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289941019/image_1289941019.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Discover why SCHD is a clear buy with a look at its top 10 holdings and why they make it an attractive investment opportunity right now.",
      "url": "https://finnhub.io/api/news?id=3b68bfa866454efa7af7ce3949bd40eddda968966891067ff52185ad91becf1d"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug",
    "summary": "The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.",
    "url": "https://finnhub.io/api/news?id=97dfe291c15cf5a857ca6a4e8b29154581b23d4de4791c5522b2f89782522693",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736421540,
      "headline": "Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug",
      "id": 132349846,
      "image": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.",
      "url": "https://finnhub.io/api/news?id=97dfe291c15cf5a857ca6a4e8b29154581b23d4de4791c5522b2f89782522693"
    }
  }
]